Symbols

CBUS

Cibus·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 0

High Gross Profit Margin

Revenue Beats Expectation

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CBUS

Cibus Inc.

A biotechnology company with gene editing technology

Industry

Chemicals

Established Date

01/08/2010

Listing Date

07/20/2017

Exchange

NASDAQ Stock Exchange

Full-time Employees

118

Fiscal Year Ends

12-31

Website

www.cibus.com

Security Type

Common stock

Office address

6455 Nancy Ridge Drive, San Diego, CA 92121

Business

Introduction

Cibus Inc., incorporated in Delaware on January 8, 2010, is a wholly owned subsidiary of Cellectis S.A. The company is a leading agricultural biotechnology company that utilizes proprietary gene editing technology to develop plant traits for major crops, initially focusing on herbicide tolerance traits in rice. Its business model is to license these traits to seed companies, while also advancing sustainable ingredients programs.

Company Financials

EPS

CBUS has released its 2025 Q4 earnings. EPS was reported at -0.59, versus the expected -0.23, missing expectations. The chart below visualizes how CBUS has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

CBUS has released its 2025 Q4 earnings report, with revenue of 1.06M, reflecting a YoY change of -12.79%, and net profit of -31.95M, showing a YoY change of -23.81%. The Sankey diagram below clearly presents CBUS's revenue sources and cost distribution.